行情

BDSI

BDSI

BioDelivery科学国际
NASDAQ

实时行情|Nasdaq Last Sale

2.910
-0.100
-3.32%
盘后: 2.910 0 0.00% 16:35 11/26 EST
开盘
2.980
昨收
3.010
最高
2.985
最低
2.840
成交量
90.07万
成交额
--
52周最高
4.990
52周最低
2.840
市值
2.87亿
市盈率(TTM)
9.71
分时
5日
1月
3月
1年
5年
Biodelivery Sciences Intl Insider Makes $305K Stock Purchase
Broadfin Capital Llc, By: Kevin Kotler, Kevin Kotler, Managing Member, Insider at Biodelivery Sciences Intl (NASDAQ:BDSI), made a large insider buy on November 19, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and E...
Benzinga · 5天前
Biodelivery Sciences Intl Insider Makes $320K Stock Purchase
Broadfin Capital Llc, By: Kevin Kotler, Kevin Kotler, Managing Member, Insider at Biodelivery Sciences Intl (NASDAQ:BDSI), made a large insider buy on November 12, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and E...
Benzinga · 11/15 16:47
Insider Buy: Biodelivery Sciences International
MT Newswires · 11/09 13:04
--HC Wainwright Cuts BioDelivery Sciences International to Neutral From Buy, Price Target to $4.50 From $6
MT Newswires · 11/04 13:44
HC Wainwright & Co. Downgrades BioDelivery Sciences Intl to Neutral, Lowers Price Target to $4.5
HC Wainwright & Co. analyst Oren Livnat downgrades BioDelivery Sciences Intl (NASDAQ:BDSI) from Buy to Neutral and lowers the price target from $6 to $4.5.
Benzinga · 11/04 11:13
BioDelivery Sciences International (BDSI) Tops Q3 Earnings Estimates
BioDelivery (BDSI) delivered earnings and revenue surprises of 16.67% and -2.28%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/03 13:15
BioDelivery Sciences Intl Q3 EPS $0.07 Beats $0.05 Estimate, Sales $41.10M Miss $42.04M Estimate
BioDelivery Sciences Intl (NASDAQ:BDSI) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.05 by 40 percent. This is a 22.22 percent decrease over earnings of $0.09 per share
Benzinga · 11/03 12:08
BioDelivery Sciences EPS beats by $0.01, misses on revenue
BioDelivery Sciences (NASDAQ:BDSI): Q3 GAAP EPS of $0.07 beats by $0.01. Revenue of $41.09M (+4.2% Y/Y) misses by $0.95M. Shares +2.44% PM. Press Release Closed acquisition of ELYXYB, the first
Seekingalpha · 11/03 12:08
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解BDSI最新的财务预测,通过BDSI每股收益,每股净资产,每股现金流等数据分析BioDelivery科学国际近期的经营情况,然后做出明智的投资选择。
分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

12.50%强力推荐
75.00%买入
12.50%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测BDSI价格均价为6.93,最高价位10.00,最低价为4.500。
最高10.00
均价6.93
最低4.500
现价2.910
EPS
实际EPS
预期EPS
0.030.050.070.10
Q4 2020
Q1 2021
Q2 2021
Q3 2021
    0
Q4 2021
机构持股
总机构数: 220
机构持股: 7,331.66万
持股比例: 74.21%
总股本: 9,879.59万
类型机构数股数
增持
53
424.49万
建仓
18
274.54万
减持
44
387.07万
平仓
9
112.25万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
-0.45%
制药与医学研究
+0.44%
高管信息
Non-Executive Chairman/Independent Director
Peter Greenleaf
President
Scott Plesha
Chief Executive Officer/Director
Jeffrey Bailey
Chief Financial Officer/Chief Accounting Officer
John Golubieski
Senior Vice President
Joseph Lockhart
Senior Vice President
Kevin Ostrander
Chief Compliance Officer/General Counsel/Secretary
James Vollins
Other
Thomas Smith
Director
Mark Sirgo
Independent Director
Todd Davis
Independent Director
Kevin Kotler
Independent Director
Vanila Singh
Independent Director
William Watson
暂无数据
  • 全部
  • 财务报告
  • 内部人交易
更多
BDSI 简况
BioDelivery Sciences International, Inc.是一家专业制药公司。该公司自行或与第三方合作开发并销售批准疗法的应用,以利用药物输送技术解决未满足的医疗需求。该公司主要开发针对疼痛管理和成瘾方向的药品。该公司的产品采用BioErodible MucoAdhesive(BEMA)药物输送技术。BEMA一种用于颊黏膜(脸颊内膜)的小型易蚀聚合物膜。该公司美国食品和药物管理局(FDA)批准产品ONSOLIS(口腔可溶贴膜)以及其批准产品BUNAVAIL(丁丙诺啡和纳洛酮颊膜)颊膜及BELBUCA(丁丙诺啡)颊膜均采用BEMA技术。

微牛提供BioDelivery Sciences International, Inc.(NASDAQ-BDSI)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的BDSI股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易BDSI股票基本功能。